Chelsie Derman is an assistant editor for HCPLive who covers psychiatry, sleep medicine, and geriatrics. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.
She can be reached at cderman@mjhlifesciences.com
Patients Unsatisfied After Mandatory Adalimumab Biosimilar Transition
December 5th 2023Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.
Read More
CBT Linked to Improving Depression Symptoms in Adults with Type 1 Diabetes
December 4th 2023In a new study focusing on adults with type 1 diabetes and mild-moderate depressive symptomatology, a CBT program helped depression symptoms, quality of life, anxiety, treatment adherence, and total diabetes-related stress in emotional, physical, and impersonal subscales.
Read More
Mothers’ Mental Disorders Is Not Linked to Type 1 Diabetes in Offspring
December 4th 2023Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.
Read More
Lower Sleep Efficiency Linked to Higher HbA1c in Adolescents with Type 1 Diabetes
December 2nd 2023The study did not find an association between glycemic parameters and flow-mediated dilation, but they did find associations between lower sleep efficiency with poorer glycemic control, insulin resistance, estimated glucose disposal rate, and HbA1C.
Read More
FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment
November 29th 2023The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.
Read More
In a new study, the highest socioeconomic group was associated with lower morality rates for all-cause mortality, lower morality from natural causes, and higher mortality from external causes. Although the data does not show a significant link between the role of socioeconomic position with the mortality rate among people with mental disorders.
Read More
COVID-19 Vaccine Safe for Patients with Hepatitis C Virus-Related Liver Disease
November 22nd 2023After receiving the COVID-19 vaccination, the antibody titers of patients with cirrhosis and hepatocellular carcinoma were significantly reduced compared to patients with chronic hepatitis C patients.
Read More
Smartphone Notifications Helps Prevent Missed Doses for Gout Medication
November 20th 2023The 2 groups—the active control group who received smartphone notifications about general health advice and the intervention group who receive notifications on adherence-targeted information—did not have significant differences in serum urate levels.
Read More
Low-Cost Standard-Field Fundus Camera Viable for Proliferative Sickle Cell Retinopathy Screening
November 18th 2023Standard-Field Fundus Camera performs well in detecting proliferative sickle cell retinopathy, but performs poorly detecting non-proliferative sickle cell retinopathy, a new study found.
Read More
Vision Impairment Associated with Developing Mental Health Conditions
November 17th 2023After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.
Read More
Gross Hematuria Observed in Patients with IgA Nephropathy After COVID-19 Vaccination
November 16th 2023In the new study, 71% of the patients who developed gross hematuria after a COVID-19 vaccination were females, and for 92% of the patients, the investigators observed gross hematuria had developed after the second or subsequent vaccinations.
Read More
Study Supports the Efficacy, Safety of Ravulizumab for Patients with IgA Nephropathy
November 16th 2023The ravulizumab group had a proteinuria reduction of 40.3% while the placebo group had a reduction of 10.9% by week 26, highlighting ravulizumab’s effectiveness in treating patients with IgA Nephropathy.
Read More
Neighborhood Disadvantages Do Not Influence Minority Children’s High Autism Spectrum Diagnoses
November 15th 2023Children of mothers in minority group were associated with a higher likelihood of ASD diagnosis, but only children of White mothers had ASD associated with neighborhood disadvantages.
Read More
FDA Approves Defencath to Reduce Catheter Bloodstream Infections in Adults Receiving Hemodialysis
November 15th 2023On November 15, 2023, the FDA approved Defencath. The new drug can reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.
Read More